Open AccessMultiple Administrations of Itraconazole Increase Plasma Exposure to Pyrotinib in Chinese Healthy Adults
Author(s) -
Yueyue Liu,
Qian Zhang,
Chao Lü,
Wei Hu
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
ISSN - 1177-8881
DOI - 10.2147/dddt.s312310
Subject(s) - itraconazole , cmax , pharmacokinetics , pharmacology , adverse effect , medicine , cyp3a4 , antifungal , dermatology , cytochrome p450 , metabolism
Pyrotinib, an irreversible human epidermal growth factor receptor 2 (HER2), is a epidermal growth factor receptor double-target tyrosine kinase inhibitor used for treating HER2-positive breast cancer. This study aimed to evaluate the impact of the strong CYP3A4 inhibitor itraconazole on the safety and pharmacokinetics of pyrotinib in Chinese healthy adults.